These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 22006152

  • 1. Penile paraffinoma developing during treatment with pegylated interferon alfa-2a for chronic hepatitis C virus infection.
    Bachmeyer C, Moguelet P, Gombeaud T, Sbidian E, Aractingi S.
    Arch Dermatol; 2011 Oct; 147(10):1232-3. PubMed ID: 22006152
    [No Abstract] [Full Text] [Related]

  • 2. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
    Hu CC, Chien RN.
    Aliment Pharmacol Ther; 2013 Feb; 37(4):492. PubMed ID: 23336679
    [No Abstract] [Full Text] [Related]

  • 3. [Cutaneous necrosis due to injection of interferon-alpha 2b in a patient with chronic hepatitis C].
    Castellanos González M, Pérez Carreras M, Muñoz Gómez R, Castellano Tortajada G.
    Gastroenterol Hepatol; 2011 Oct; 34(8):584-5. PubMed ID: 21641684
    [No Abstract] [Full Text] [Related]

  • 4. Reversible sudden sensorineural hearing loss during chronic hepatitis C treatment with pegylated interferon/ribavirin.
    Papastergiou V, Skorda L, Lisgos P, Karatapanis S.
    Acta Gastroenterol Belg; 2011 Dec; 74(4):582-4. PubMed ID: 22319972
    [No Abstract] [Full Text] [Related]

  • 5. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ, Romagosa R, Vincek V.
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract] [Full Text] [Related]

  • 6. Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials.
    Chou R, Carson S, Chan BK.
    J Viral Hepat; 2008 Aug; 15(8):551-70. PubMed ID: 18482285
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index.
    Testino G, Gentile R, Ansaldi F, Borro P, Ravetti G, Icardi G, Sumberaz A.
    Panminerva Med; 2009 Jun; 51(2):135-6. PubMed ID: 19776716
    [No Abstract] [Full Text] [Related]

  • 10. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J.
    N Engl J Med; 2002 Sep 26; 347(13):975-82. PubMed ID: 12324553
    [Abstract] [Full Text] [Related]

  • 11. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W.
    Eur J Gastroenterol Hepatol; 2013 May 26; 25(5):601-5. PubMed ID: 23263720
    [Abstract] [Full Text] [Related]

  • 12. Autoimmune fulminant hepatic failure in chronic hepatitis C during Peg-interferon-alpha 2b plus ribavirin treatment showing histological heterogeneity.
    Yasui S, Fujiwara K, Yokosuka O.
    Dig Liver Dis; 2011 Aug 26; 43(8):666-7. PubMed ID: 21435960
    [No Abstract] [Full Text] [Related]

  • 13. Repeated Panniculitis Induced by Pegylated Interferon Alpha 2a in a Patient with Chronic Hepatitis C.
    Song JS, Sohn JH, Jeong JY, Min JH, Choi WS, Kim OZ, Pyo JY.
    Korean J Gastroenterol; 2016 May 25; 67(5):272-276. PubMed ID: 27206440
    [Abstract] [Full Text] [Related]

  • 14. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
    Berak H, Laskus T, Kołakowska-Rządzka A, Wasilewski M, Stańczak JJ, Bardadin K, Walewska-Zielecka B, Horban A.
    Adv Med Sci; 2014 Sep 25; 59(2):261-5. PubMed ID: 25117425
    [Abstract] [Full Text] [Related]

  • 15. Erythema gyratum repens induced by pegylated interferon alfa for chronic hepatitis C.
    Rongioletti F, Fausti V, Parodi A.
    Arch Dermatol; 2012 Oct 25; 148(10):1213-4. PubMed ID: 23069974
    [No Abstract] [Full Text] [Related]

  • 16. Secondary hyperpigmentation during interferon alfa treatment for chronic hepatitis C virus infection.
    Tsilika K, Tran A, Trucchi R, Pop S, Anty R, Cardot-Leccia N, Lacour JP, Ortonne JP, Passeron T.
    JAMA Dermatol; 2013 Jun 25; 149(6):675-7. PubMed ID: 23553009
    [Abstract] [Full Text] [Related]

  • 17. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy.
    Gordon A, Menahem S, Mitchell J, Jenkins P, Dowling J, Roberts SK.
    Nephrol Dial Transplant; 2004 Aug 25; 19(8):2155. PubMed ID: 15252182
    [No Abstract] [Full Text] [Related]

  • 18. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
    Mousa N, Besheer T, Gad Y, Elbendary A, Mokbel T, Abdel-Aziz A.
    J Ocul Pharmacol Ther; 2013 Apr 25; 29(3):345-8. PubMed ID: 23113644
    [Abstract] [Full Text] [Related]

  • 19. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
    Quinn D, Kuchler E, Deming P, Arora S.
    Psychosomatics; 2012 Apr 25; 53(4):400-1. PubMed ID: 22748752
    [No Abstract] [Full Text] [Related]

  • 20. Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
    Yang WS, Chu PL, Liu CH, Chung GB, Wu KD.
    J Clin Gastroenterol; 2008 Jan 25; 42(1):112-3. PubMed ID: 18097301
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.